- Lyell Immunopharma to Participate in BofA Securities Health Care Conference
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
- Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
- Lyell Immunopharma Announces Participation in March Investor Conferences
- Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
- Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
- Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
- Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
More ▼
Key statistics
On Thursday, Lyell Immunopharma Inc (LYEL:NSQ) closed at 2.68, -32.49% below its 52-week high of 3.97, set on Jun 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.52 |
---|---|
High | 2.70 |
Low | 2.50 |
Bid | 2.30 |
Offer | 2.96 |
Previous close | 2.50 |
Average volume | 703.04k |
---|---|
Shares outstanding | 254.94m |
Free float | 207.35m |
P/E (TTM) | -- |
Market cap | 637.34m USD |
EPS (TTM) | -0.9057 USD |
Data delayed at least 15 minutes, as of May 09 2024 21:00 BST.
More ▼